Insider · CIK 0001961273
Lamy Patrick
officer
Files at AKRO (Akero Therapeutics, Inc.). First filing Dec 12, 2024, latest Mar 5, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 4
$0 bought, $391k sold
Signals
This insider’s open-market buys and sells, scored.
| Score | Side | Company | Value | Shares | Holdings change | Price context | Filed |
|---|---|---|---|---|---|---|---|
| 2Weak | sell 610b5-1 | AKRO Akero Therapeutics, Inc. | $48k | 1,000 | -3% | - | |
| 14Weak | sell 510b5-1 | AKRO Akero Therapeutics, Inc. | $285k | 5,000 | -13% | - | |
| 15Weak | sell 610b5-1 | AKRO Akero Therapeutics, Inc. | $29k | 1,000 | -3% | - | |
| 35Weak | sell 6 | AKRO Akero Therapeutics, Inc. | $28k | 925 | -5% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 3, 2025 | AKRO Akero Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +1,000 | $19.87 | $20k | 34,492 | Mar 5, 2025 |
| Mar 3, 2025 | AKRO Akero Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -1,000 | $48.09 | $48k | 33,492 | Mar 5, 2025 |
| Mar 3, 2025 | AKRO Akero Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -1,000 | $0.00 | $0 | 78,182 | Mar 5, 2025 |
| Dec 31, 2024 | AKRO Akero Therapeutics, Inc. | AGrant or award Common Stock10b5-1 | +234 | $19.69 | $4,607 | 34,492 | Jan 29, 2025 |
| Jan 27, 2025 | AKRO Akero Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +4,000 | $19.87 | $79k | 38,492 | Jan 29, 2025 |
| Jan 27, 2025 | AKRO Akero Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -5,000 | $57.03 | $285k | 33,492 | Jan 29, 2025 |
| Jan 27, 2025 | AKRO Akero Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -4,000 | $0.00 | $0 | 79,182 | Jan 29, 2025 |
| Dec 16, 2024 | AKRO Akero Therapeutics, Inc. | AGrant or award Common Stock10b5-1 | +17,400 | $0.00 | $0 | 35,258 | Dec 18, 2024 |
| Dec 16, 2024 | AKRO Akero Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -1,000 | $29.13 | $29k | 34,258 | Dec 18, 2024 |
| Dec 16, 2024 | AKRO Akero Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative10b5-1 | +52,100 | $0.00 | $0 | 52,100 | Dec 18, 2024 |
| Dec 10, 2024 | AKRO Akero Therapeutics, Inc. | SOpen-market sale Common Stock | -925 | $30.79 | $28k | 17,858 | Dec 12, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.